<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>During the last 15 years, we have used the National <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Institute (NCI) 89-C-41 protocol in patients aged younger than 21 years with Burkitt's <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e>) and diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>According to the Magrath staging system, patients were classified as low and high risk </plain></SENT>
<SENT sid="2" pm="."><plain>Low-risk received three cycles of the CODOX-M regimen; high-risk patients received four alternating cycles with the CODOX-M and IVAC regimens </plain></SENT>
<SENT sid="3" pm="."><plain>Thirty-five patients entered the study: 32 (91%) achieved complete remission (CR); three were non-responders and died and one patient died in CR </plain></SENT>
<SENT sid="4" pm="."><plain>Two responders relapsed after 2 months and one presented early B <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> 33 months from the end of therapy </plain></SENT>
<SENT sid="5" pm="."><plain>The 5-year overall survival and event free-survival are 83% and 80%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>No late toxicity was registered </plain></SENT>
<SENT sid="7" pm="."><plain>In our experience with a median follow-up of 11 years, the NCI 89-C-41 protocol has confirmed its high cure rate in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> children and adolescents </plain></SENT>
</text></document>